Do vasoactive medications impact donor hearts clinical outcomes in pediatric heart transplantation?

Abstract

There is limited data examining donor vasopressor and/or inotrope medications (vasoactives) on pediatric orthotopic heart transplant (OHT) outcomes. We aim to evaluate the effects of vasoactives on pediatric OHT outcomes. The United Network for Organ Sharing database was retrospectively reviewed from January 2000 to March 2018 for donor hearts. Exclusion criteria included multiorgan transplants and recipient age >18. Donors receiving vasoactives at the time of procurement were compared to donors not on vasoactives, including the number of vasoactives and the type. End-points of interest were survival at 30 days and 1year as well as post-transplant rejection at 1year. Logistic and Cox models were used to quantify survival end-points. Of 6462 donors, 3187 (49.3%) were receiving at least one vasoactive. Comparing any vasoactive medication versus none, there was no difference in 30-day survival (p= .27), 1 year survival (p= .89), overall survival (p= .68), or post-transplant rejection (p= .98). There was no difference in 30-day survival for donors receiving 2 or more vasoactive infusions (p= .89), 1 year survival (p= .53), overall survival (p= .75), or post-transplant rejection at 1year (p= .87). Vasopressin was associated with decreased 30-day mortality (OR=0.22; p= .028), dobutamine with decreased 1-year mortality (OR=0.37; p= .036), overall survival (HR=0.51; p= .003), and decreased post-transplant rejection (HR=0.63; p= .012). There is no difference in pediatric OHT outcomes when the cardiac donor is treated with vasoactive infusions at procurement. Vasopressin and dobutamine were associated with improved outcomes. This information can be used to guide medical management and donor selection.